Akeso’s ivonescimab, a PD-1/VEGF bispecific, reduced the risk of death by 34% versus a PD-1 inhibitor–chemotherapy comparator in a Phase 3 study in China for previously untreated advanced squamous non-small cell lung cancer. Results were presented at ASCO and published simultaneously in The Lancet. In the Harmoni-6 interim analysis, the regimen of ivonescimab plus chemotherapy beat the control arm on overall survival, with a prespecified statistical threshold met. The data were framed as a critical readout for a China-based dataset that is increasingly used by developers to establish clinical leadership. The outcome further intensifies competition in the emerging PD-(L)1xVEGF bispecific class and may influence global development strategy for the regimen beyond China.